Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Shares Issued: 2017-2025

Historic Shares Issued for Crinetics Pharmaceuticals (CRNX) over the last 7 years, with Sep 2025 value amounting to $3.1 million.

  • Crinetics Pharmaceuticals' Shares Issued fell 93.59% to $3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $539.0 million, marking a year-over-year increase of 16.62%. This contributed to the annual value of $970.0 million for FY2024, which is 162.87% up from last year.
  • Crinetics Pharmaceuticals' Shares Issued amounted to $3.1 million in Q3 2025, which was up 7.08% from $2.9 million recorded in Q2 2025.
  • Crinetics Pharmaceuticals' Shares Issued's 5-year high stood at $528.5 million during Q4 2024, with a 5-year trough of -$42,000 in Q2 2021.
  • In the last 3 years, Crinetics Pharmaceuticals' Shares Issued had a median value of $3.8 million in 2025 and averaged $100.3 million.
  • Its Shares Issued has fluctuated over the past 5 years, first slumped by 100.04% in 2021, then soared by 275,040.48% in 2022.
  • Crinetics Pharmaceuticals' Shares Issued (Quarterly) stood at $162.0 million in 2021, then soared by 275,040.48% to -$13,000 in 2022, then slumped by 99.03% to $28.8 million in 2023, then skyrocketed by 1,738.31% to $528.5 million in 2024, then plummeted by 93.59% to $3.1 million in 2025.
  • Its last three reported values are $3.1 million in Q3 2025, $2.9 million for Q2 2025, and $4.4 million during Q1 2025.